| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8726626 | Gastroenterology | 2018 | 55 Pages |
Abstract
In an analysis of data from Phase 3 studies of patients with moderate to severe CD, we found serum concentrations of ustekinumab to be proportional to dose and associate with treatment efficacy. Concentrations of ustekinumab did not seem to be affected by cotreatment with immunomodulators. Clinicaltrials.gov no. NCT01369329 (UNITI 1), NCT01369342 (UNITI 2), and NCT01369355 (IM-UNITI).
Keywords
CDAIevery 8 weeksTNFROCIL23creactive proteinIBDMSDECLIAIL126-MercaptopurineMTXSES-CDAZA6-MPAUCazathioprineelectrochemiluminescent immunoassayinterleukin 12interleukin 23Crohn’s diseaseInflammatory bowel diseaseIntravenoussubcutaneousCrohn’s Disease Activity IndexPharmacokinetic(s)tumor necrosis factorMethotrexateCRPMeso Scale Discoveryreceiver operating characteristic
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Omoniyi J. Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long-Long Gao, Hugh M. Davis, Stephen B. Hanauer, Brian G. Feagan, Subrata Ghosh, William J. Sandborn,